CJC-1295 the science.

CJC-1295 is a modified peptide based on the first 29 amino acids of human GHRH — the hypothalamic hormone that signals the pituitary gland to release growth hormone (GH). The molecule carries amino-acid substitutions that resist enzymatic breakdown, and some versions add a drug-affinity-complex (DAC) group that binds circulating albumin to prolong its half-life. These changes are the focus of research into how a GHRH analog can sustain its signal far longer than native GHRH.

The research rationale is to stimulate the body’s endogenous GH axis — rather than supplying GH directly — so investigators can study how prolonged GHRH-receptor activation affects GH and IGF-1 dynamics. CJC-1295 is an investigational compound, not an approved medicine.

CJC-1295 research is organized around the hypothalamic-pituitary GH axis:

• GHRH-receptor activation — binding the pituitary GHRH receptor is studied for how it triggers GH synthesis and release.
• Pulsatile GH release — because it works upstream, researchers examine whether GH is released in a pulsatile pattern that preserves the axis’s natural feedback.
• IGF-1 response — downstream IGF-1, the main mediator of GH’s peripheral effects, is tracked as a marker of sustained signaling.

CJC-1295 has both preclinical and early-phase human research:

• Healthy-adult pharmacokinetics (2006). A study in the Journal of Clinical Endocrinology & Metabolism reported that single doses of CJC-1295 produced prolonged elevations of GH and IGF-1 in healthy adults, characterizing its extended duration of action.
• Receptor & durability work. Earlier preclinical research examined the albumin-binding modification and how it extends the molecule’s circulating half-life.

These human studies are early-phase and investigational. CJC-1295 is not FDA-approved, and this material is supplied for research use only.

CJC-1295 is an investigational GHRH analog. Published evidence includes early-phase human pharmacokinetic studies in addition to preclinical work, but it is not FDA-approved and no approved indication, dosing, or therapeutic claim applies. CJC-1295 is supplied strictly as a research material for laboratory investigation.